NO2947086T3 - - Google Patents

Info

Publication number
NO2947086T3
NO2947086T3 NO14836782A NO14836782A NO2947086T3 NO 2947086 T3 NO2947086 T3 NO 2947086T3 NO 14836782 A NO14836782 A NO 14836782A NO 14836782 A NO14836782 A NO 14836782A NO 2947086 T3 NO2947086 T3 NO 2947086T3
Authority
NO
Norway
Application number
NO14836782A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2947086T3 publication Critical patent/NO2947086T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO14836782A 2013-08-12 2014-08-11 NO2947086T3 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013167600 2013-08-12
PCT/JP2014/071158 WO2015022926A1 (ja) 2013-08-12 2014-08-11 新規な縮合ピリミジン化合物又はその塩

Publications (1)

Publication Number Publication Date
NO2947086T3 true NO2947086T3 (zh) 2018-06-02

Family

ID=52468312

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14836782A NO2947086T3 (zh) 2013-08-12 2014-08-11

Country Status (23)

Country Link
US (1) US9580432B2 (zh)
EP (1) EP2947086B1 (zh)
JP (1) JP6035423B2 (zh)
KR (1) KR101828187B1 (zh)
CN (1) CN105452257B (zh)
AU (1) AU2014307437B2 (zh)
BR (1) BR112016002069B1 (zh)
CA (1) CA2921208C (zh)
DK (1) DK2947086T3 (zh)
ES (1) ES2661733T3 (zh)
HK (1) HK1217703A1 (zh)
HU (1) HUE036834T2 (zh)
MX (1) MX360498B (zh)
MY (1) MY171831A (zh)
NO (1) NO2947086T3 (zh)
PH (1) PH12015502737B1 (zh)
PL (1) PL2947086T3 (zh)
PT (1) PT2947086T (zh)
RU (1) RU2666349C2 (zh)
SG (1) SG11201600048VA (zh)
TR (1) TR201802875T4 (zh)
TW (1) TWI585089B (zh)
WO (1) WO2015022926A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12019500143A1 (en) 2013-08-23 2020-03-02 Neupharma Inc Certain chemical entities, compositions, and methods
KR101858421B1 (ko) * 2015-01-30 2018-05-15 다이호야쿠힌고교 가부시키가이샤 면역 질환의 예방 및/또는 치료제
AU2016213031B2 (en) * 2015-01-30 2018-12-13 Taiho Pharmaceutical Co., Ltd. Novel salt of fused pyrimidine compound and crystal thereof
CA2997051C (en) * 2015-09-01 2020-03-24 Taiho Pharmaceutical Co., Ltd. Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
US9834561B2 (en) * 2015-10-28 2017-12-05 Scinopharm Taiwan, Ltd. Process for preparing ibrutinib and its intermediates
BR112018016724B1 (pt) 2016-02-23 2024-02-20 Taiho Pharmaceutical Co., Ltd Composto de pirimidina condensado ou sal do mesmo, seus usos, inibidor de ret, agente antitumor e composição farmacêutica
CA3033370A1 (en) * 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
US11696917B2 (en) 2017-02-28 2023-07-11 Taiho Pharmaceutical Co., Ltd. Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound
AU2020206640B2 (en) * 2019-01-11 2022-09-08 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound or salt thereof
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
JP7304968B2 (ja) * 2019-12-19 2023-07-07 大鵬薬品工業株式会社 縮合ピリミジン化合物を有効成分とする治療剤
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022014640A1 (ja) * 2020-07-15 2022-01-20 大鵬薬品工業株式会社 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN114736207B (zh) * 2022-04-28 2023-03-31 武汉九州钰民医药科技有限公司 一种小分子her2抑制剂的制备工艺

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06004680A (es) 2003-10-27 2007-04-17 Genelabs Tech Inc Compuestos de nucleosido para el tratamiento de infecciones virales.
EP1968979A2 (en) 2005-12-08 2008-09-17 Abbott Laboratories 9-membered heterobicyclic compounds as inhibitors of protein kinases
JP2009531443A (ja) 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド α−シヌクレイン毒性の抑制
US8987233B2 (en) 2006-11-03 2015-03-24 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
EP2561875A3 (en) 2007-03-28 2013-06-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
JP2009235057A (ja) * 2007-10-31 2009-10-15 Santen Pharmaceut Co Ltd 血管新生阻害活性を有する新規インドール誘導体
KR101892989B1 (ko) 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
CN105771039B (zh) * 2011-07-15 2020-01-10 赛诺菲-安万特德国有限公司 药物输送装置
DK2657233T3 (da) 2012-01-19 2014-09-22 Taiho Pharmaceutical Co Ltd 3,5-disubstitueret alkynylbenzenforbindelse og salt deraf
CN104250250A (zh) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-芳香胺基嘧啶类化合物及其抗肿瘤用途

Also Published As

Publication number Publication date
CA2921208C (en) 2018-02-20
KR20160038891A (ko) 2016-04-07
CN105452257A (zh) 2016-03-30
MY171831A (en) 2019-11-01
TWI585089B (zh) 2017-06-01
US20160115168A1 (en) 2016-04-28
CN105452257B (zh) 2017-09-05
DK2947086T3 (en) 2018-03-19
PH12015502737A1 (en) 2016-03-07
JPWO2015022926A1 (ja) 2017-03-02
KR101828187B1 (ko) 2018-02-09
WO2015022926A1 (ja) 2015-02-19
EP2947086A4 (en) 2016-06-22
PT2947086T (pt) 2018-03-09
HK1217703A1 (zh) 2017-01-20
PL2947086T3 (pl) 2018-06-29
CA2921208A1 (en) 2015-02-19
PH12015502737B1 (en) 2016-03-07
US9580432B2 (en) 2017-02-28
TW201536786A (zh) 2015-10-01
SG11201600048VA (en) 2016-03-30
TR201802875T4 (tr) 2018-03-21
AU2014307437A1 (en) 2016-01-21
JP6035423B2 (ja) 2016-11-30
EP2947086B1 (en) 2018-01-03
MX2016001845A (es) 2016-05-16
RU2666349C2 (ru) 2018-09-07
ES2661733T3 (es) 2018-04-03
HUE036834T2 (hu) 2018-08-28
BR112016002069A2 (pt) 2017-08-01
MX360498B (es) 2018-11-05
AU2014307437B2 (en) 2016-12-15
RU2015156524A (ru) 2017-09-14
BR112016002069B1 (pt) 2020-08-18
EP2947086A1 (en) 2015-11-25

Similar Documents

Publication Publication Date Title
AP2016009275A0 (zh)
BR112015007533A2 (zh)
BR102016010778A2 (zh)
BR112014017733A2 (zh)
BR112014018502A2 (zh)
BR112014017739A2 (zh)
BR112014018516A2 (zh)
BR112014020341A2 (zh)
BR112014017855A2 (zh)
BR112014017765A2 (zh)
BR112014017669A2 (zh)
BR112014021878A2 (zh)
NO2947086T3 (zh)
BR112015030897A2 (zh)
BR112014017901A2 (zh)
BR112014019204A2 (zh)
BR112016001246A2 (zh)
BR112015015948A2 (zh)
BR112014017722A2 (zh)
BR112014018578A2 (zh)
BR112014017653A2 (zh)
BR112014017794A2 (zh)
BR112014017601A2 (zh)
BR112015015312A2 (zh)
BR112014018496A2 (zh)